is also developing the AKT inhibitor in phase 3 trials in combination with paclitaxel as first-line treatment for locally advanced or metastatic TNBC, and also has late-stage studies on the go in ...

So far, no AKT inhibitors have been brought to market ... as well as the late-stage CAPItello-281 trial on the go in hormone-sensitive prostate cancer. The drug has been listed among Clarivate's ...

Jeżeli akt oskarżenia odpowiada warunkom formalnym, prezes sądu zarządza doręczenie jego odpisu oskarżonemu, wzywając go do składania wniosków dowodowych w terminie 7 dni od doręczenia mu aktu ...